PharmaVision PylopassNew Vision for your health
REDUCE THE RISK OF GASTRITIS AND PEPTIC ULCERS
Helicobacter Pylori is infecting 50% of the population. Helicobacter Pylori can cause gastritis and peptic ulcers, and if untreated it could lead to gastric cancer. The surface structures on Pylopass contains adhesion molecules that recognize and adhere to surface receptors on H. Pylori. After coaggregation in the stomach has occurred, the entire coaggregation is excreted from the body through the digestive tract.
Pylopass is biologically active product and nutritional product which reduces concentration of H. Pylori in the stomach lining and upper part of the small intestine.
Pylopass contains 20 billion specially selected and heat-inactivated Lactobacillus reuteri DSMZ 17648 which:
- reduce H. Pylori,
- alleviate symptoms related to H. Pylori infection such as:excessive burping, feeling bloated, nausea or vomiting, lack of appetite, bad breath.
APPROVED EU HEALTH CLAIMS:
Pylopass also contains zinc, which contributes to:
- The normal acid-base metabolism
- The normal function of the immune system
- Normal carbohydrate metabolism and metabolism of fatty acids.
Every capsule contains Lactobacillus reuteri DSMZ 17648 (heat-inactivated) – 200mg zinc citrate – 4,8 mg
RECOMMENDED DOSE: 1 capsule PHARMAVISION Pylopass per day to be ingested orally with a glass of water for 14 days.
Pylopass is clinicaly proven to treat H. Pylori.
Produced for Pharma Vision Europe by Biocare Copenhagen A/S,Ltd., 2200 Copenhagen, Denmark
14 capsules – 450 mg each capsule